Value of cerebrospinal fluid α-synuclein species as biomarker in Parkinson's diagnosis and prognosis
(2016) In Biomarkers in Medicine 10(1). p.35-49- Abstract
Since diagnosis of Parkinson's disease (PD) is mostly based on clinical criteria, it is almost impossible to formulate an early diagnosis, as well as a timely differential diagnosis versus other parkinsonisms. A great effort in searching reliable biomarkers both for early diagnosis and prognosis in PD is currently ongoing. Cerebrospinal fluid has been widely investigated as potential source for such biomarkers, with particular emphasis on α-synuclein (α-syn) species. We reviewed all the clinical studies carried out so far on cerebrospinal fluid quantification of α-syn species in PD. Current evidence supports the value of total and oligomeric α-syn in PD diagnosis and in the differential diagnosis of PD and other parkinsonisms.... (More)
Since diagnosis of Parkinson's disease (PD) is mostly based on clinical criteria, it is almost impossible to formulate an early diagnosis, as well as a timely differential diagnosis versus other parkinsonisms. A great effort in searching reliable biomarkers both for early diagnosis and prognosis in PD is currently ongoing. Cerebrospinal fluid has been widely investigated as potential source for such biomarkers, with particular emphasis on α-synuclein (α-syn) species. We reviewed all the clinical studies carried out so far on cerebrospinal fluid quantification of α-syn species in PD. Current evidence supports the value of total and oligomeric α-syn in PD diagnosis and in the differential diagnosis of PD and other parkinsonisms. Conversely, the role of α-syn species in PD prognosis remains unsatisfactory.
(Less)
- author
- Parnetti, Lucilla
; Cicognola, Claudia
LU
; Eusebi, Paolo and Chiasserini, Davide
- publishing date
- 2016-01-01
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- cerebrospinal fluid biomarkers, cognitive impairment, disease progression, early diagnosis, motor symptoms, Parkinson's disease, parkinsonisms, prognosis, α-synuclein
- in
- Biomarkers in Medicine
- volume
- 10
- issue
- 1
- pages
- 15 pages
- publisher
- Future Medicine Ltd.
- external identifiers
-
- scopus:84951771245
- pmid:26643452
- ISSN
- 1752-0363
- DOI
- 10.2217/bmm.15.107
- language
- English
- LU publication?
- no
- id
- c7e6ac65-5488-4bb8-96c1-d8d503247dff
- date added to LUP
- 2020-02-25 09:51:28
- date last changed
- 2024-06-26 12:17:37
@article{c7e6ac65-5488-4bb8-96c1-d8d503247dff, abstract = {{<p>Since diagnosis of Parkinson's disease (PD) is mostly based on clinical criteria, it is almost impossible to formulate an early diagnosis, as well as a timely differential diagnosis versus other parkinsonisms. A great effort in searching reliable biomarkers both for early diagnosis and prognosis in PD is currently ongoing. Cerebrospinal fluid has been widely investigated as potential source for such biomarkers, with particular emphasis on α-synuclein (α-syn) species. We reviewed all the clinical studies carried out so far on cerebrospinal fluid quantification of α-syn species in PD. Current evidence supports the value of total and oligomeric α-syn in PD diagnosis and in the differential diagnosis of PD and other parkinsonisms. Conversely, the role of α-syn species in PD prognosis remains unsatisfactory.</p>}}, author = {{Parnetti, Lucilla and Cicognola, Claudia and Eusebi, Paolo and Chiasserini, Davide}}, issn = {{1752-0363}}, keywords = {{cerebrospinal fluid biomarkers; cognitive impairment; disease progression; early diagnosis; motor symptoms; Parkinson's disease; parkinsonisms; prognosis; α-synuclein}}, language = {{eng}}, month = {{01}}, number = {{1}}, pages = {{35--49}}, publisher = {{Future Medicine Ltd.}}, series = {{Biomarkers in Medicine}}, title = {{Value of cerebrospinal fluid α-synuclein species as biomarker in Parkinson's diagnosis and prognosis}}, url = {{http://dx.doi.org/10.2217/bmm.15.107}}, doi = {{10.2217/bmm.15.107}}, volume = {{10}}, year = {{2016}}, }